63 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.
The next term ends in Aug 2039. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2039
Next term end
7
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends no later than Aug 2039 · Low confidence
Also notable
Ends Jul 2042 · High confidence
Also notable
Ends no later than Jul 2042 · Medium confidence
Also notable
Ends no later than Apr 2043 · Low confidence
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
US 11,633,496
Cited by 82 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2039. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
US 11,638,761
Cited by 90 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2042.
Anti-Transferrin Receptor (TFR) Antibody and Uses Thereof
US 11,648,318
Cited by 81 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2042. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Muscle Targeting Complexes and Formulations for Treating Myotonic Dystrophy
US 12,788,822
A family of 6 related applications built on the 2026 grant. Too new for citation comparison; protection runs to 2043. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 13 to 20, 2026 · next Dec 13
- 1 fee due Mar 19, 2027The maintenance fee for Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy (US 11,759,525) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 4 fees due Apr 3 to 24, 2027 · next Apr 3
- 3 fees due Jun 5 to 19, 2027 · next Jun 5
- 1 fee due Aug 27, 2027The maintenance fee for Muscle Targeting Complexes and Uses Thereof for Treating Myotonic Dystrophy (US 11,911,484) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
- 1 fee due Sep 19, 2027The maintenance fee for Muscle Targeting Complexes and Formulations for Treating Myotonic Dystrophy (US 11,931,421) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy (US 11,969,475) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
- 5 of the patents on this record were granted since Aug 21, 2026
What they patent
The largest of its 7 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Muscle Targeting Complexes and Uses Thereof for Treating Myotonic Dystrophy | 32 in force | to Sep 2039 |
| Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies | 23 in force | to Jul 2042 |
| Muscle Targeting Complexes and Formulations for Treating Myotonic Dystrophy | 4 in force | to Apr 2043 |
| Muscle Targeting Complexes and Formulations for Treating Facioscapulohumeral Muscular Dystrophy | 1 in force | to Dec 2044 |
| Anti-Transferrin Receptor (TFR) Antibody and Uses Thereof | 1 in force | to Jun 2043 |
| Muscle Targeting Complexes and Formulations for Treating Dystrophinopathies | 1 in force | to Jul 2042 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,111,309 | A Method of Reducing Expression of DUX4 in a Muscle Cell by Administering an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide Targeting DUX4 In force · Medium confidence | In force | Medium confidence | |
| US 11,168,141 | Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies In force · Medium confidence | In force | Medium confidence | |
| US 11,248,056 | Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies In force · Medium confidence | In force | Medium confidence | |
| US 11,286,305 | Complex Comprising Anti-Transferrin Receptor Antibody Covalently Linked to an Oligonucleotide That Targets DUX4 RNA In force · Medium confidence | In force | Medium confidence | |
| US 11,369,689 | Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies In force · Medium confidence | In force | Medium confidence | |
| US 11,390,682 | Methods of Intravenouisly Delivering Anti-Transferrin Antibody/Oligonucleotide Complexes to Subjects Having Muscular Dystrophy In force · High confidence | In force | High confidence | |
| US 11,497,815 | Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies In force · Medium confidence | In force | Medium confidence | |
| US 11,518,816 | Methods of Delivering an Oligonucleotide to a Subject Having Facioscapulohumeral Muscular Dystrophy In force · High confidence | In force | High confidence | |
| US 11,633,496 | Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies In force · Low confidence | In force | Low confidence | |
| US 11,795,233 | Muscle-Targeting Complex Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 63: 40 applications pending · 17 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.